Ironwood Pharmaceuticals IRWD
NASDAQ IRWD
$4.09 -0.08 (-1.92%)
As of: Sep 9, 2026 · 3:25 PM EDT

Ironwood Pharmaceuticals (IRWD) Income from Discontinued Operations (2010 - 2019)

Ironwood Pharmaceuticals' (IRWD) quarterly Income from Discontinued Operations came in at -$37.4 million in Q1 2019, down 125.73% year-over-year from $145.5 million in Q1 2018, and down 56.87% quarter-over-quarter from -$23.9 million in Q4 2018.

Analysis

Ironwood Pharmaceuticals (IRWD) Income from Discontinued Operations (2010 - 2019) Analysis & Trends

Ironwood Pharmaceuticals has disclosed Income from Discontinued Operations across 3 years of filings, most recently posting -$37.4 million for Q1 2019.

  • In Q1 2019, Income from Discontinued Operations fell 125.73% year-over-year to -$37.4 million; the TTM figure through Dec 2019 stood at -$37.4 million (up 57.56% YoY), while the FY2019 annual figure was -$37.4 million, up 57.56% from the prior year.
  • Income from Discontinued Operations came in at -$37.4 million for Q1 2019 at Ironwood Pharmaceuticals, down from -$23.9 million in the prior quarter.
  • In the past five years, Income from Discontinued Operations ranged from a high of -$16.6 million in Q1 2018 to a low of -$37.4 million in Q1 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Amgen 211.56 Bn 197.57 Bn 7.24 Bn -
2 Gilead Sciences 181.34 Bn 178.16 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.22 Bn 124.37 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.87 Bn 74.88 Bn 3.93 Bn -
5 Argenx Se 61.55 Bn 56.37 Bn 1.37 Bn -
6 Moderna 54.32 Bn 49.19 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.32 Bn 31.01 Bn 992.69 Mn -
8 Biogen 31.24 Bn 29.95 Bn 1.96 Bn -
9 Roivant Sciences 30.17 Bn 30.17 Bn 1.16 Mn -
10 Ironwood Pharmaceuticals 671.59 Mn 592.47 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 -37.44 Mn
Dec 31, 2018 -23.87 Mn
Sep 30, 2018 -22.53 Mn
Jun 30, 2018 -25.24 Mn
Mar 31, 2018 -16.59 Mn
Sep 30, 2010 6.37 Mn
Jun 30, 2010 -44,000.00